Advanced Accelerator Applications: Difference between revisions

Revision as of 22:17, 15 September 2020

Revision as of 18:47, 10 July 2021

Line 197:

99MTc-rhAnnexin V-128, a [[SPECT]] investigational candidate for the diagnosis and assessment of apoptotic and necrotic processes, which are present in a number of pathological conditions in oncology and cardiovascular disease, as well as in autoimmune disorders. 99MTc-rhAnnexin V-128 is currently in a Phase I/II trial for the diagnosis of rheumatoid arthritis and ankylosing spondylitis, as well as several Phase II studies in cardiovascular, cardio-oncology, and pulmonary indications.

177LuPSMA¹⁷⁷Lu-R2PSMA-617 and 68GaPSMA⁶⁸GaPSMA-R2617 are in development to treat, image, monitor and stage prostate cancer. PSMA-R2617 is a ligand of Prostate-Specific Membrane Antigen (PSMA), expressed on the majority of prostate tumor cells. 177LuPSMA¹⁷⁷Lu-R2PSMA-617 also known as Lutetium (^177Lu) vipivotide tetraxetan is being developed to treat prostate cancer andby binding to PSMA-617. In June 2021 it was granted a [[breakthrough therapy]] designation.<ref></ref> 68GaPSMA⁶⁸GaPSMA-R2617 is under development as itsa complementary diagnostic candidate. to ¹⁷⁷Lu-PSMA-617.

CTT1057 is an 18F-labeled investigational diagnostic candidate in development for PET imaging of prostate cancer. CTT1057 is a phosphoramidate-based peptide, which specifically binds to Prostate-Specific Membrane Antigen (PSMA), expressed on the majority of prostate tumor cells.

177LuNeoBOMB1 and 68GaNeoBOMB1 are new generation antagonist [[bombesin]] analogs in development to treat, image, monitor and stage gastrin-releasing peptide receptor (GRPR)-expressing malignancies, such as such as [[gastrointestinal stromal tumors]] (GIST), prostate cancer and breast cancer. 177LuNeoBOMB1 is a therapeutic candidate and 68GaNeoBOMB1 is its complementary diagnostic candidate.

==Millburn site==